The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | An update on the QuANTUM-First trial: quizartinib plus chemotherapy in FLT3-mutated AML
Harry Erba, MD, PhD, Duke University, Durham, NC, discusses the QuANTUM-First trial (NCT02668653), which evaluated quizartinib plus chemotherapy in newly diagnosed patients with FLT3-mutated acute myeloid leukemia (AML). The trial met its primary endpoint, showing higher overall survival (OS) in the experimental arm compared to placebo, with a hazard ratio of 0.78. Quizartinib treatment also improved relapse-free survival and the duration of remissions, though it was associated with increased toxicities. The benefits were most notable in patients under 60 years old. Quizartinib maintenance before allogeneic stem cell transplantation (alloSCT) did not improve survival compared to placebo, but it did offer a survival benefit for patients who did not undergo alloSCT. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research Funding: Forma, Novartis, Amgen, Macrogenics, Servier, Kura Oncology, ALX Oncology, Gilead, Jazz Pharma, Forty-Seven, Ascentage, Immunogen, Glycomimetics, Celgene, Agios, Daiichi Sankyo Inc., AbbVie, PTE, Sumitomo; Consultancy: Novartis, Macrogenics, Syros, Servier, Kura Oncology, Trillium, Takeda, Pfizer, Incyte, Immunogen, Glycomimetics, Genentech, BMS, Celgene, Astellas, Agios, Daiichi Sankyo Inc., AbbVie; Honoraria: Novartis, Servier, Jazz Pharma, Sunesis Pharmaceuticals, Incyte, Glycomimetics, BMS, Celgene, Agios, AbbVie; Membership on an entity’s Board of Directors or advisory committees: Glycomimetics, AbbVie; Other: BMS (Chair, Myeloid Neoplasms Repository Study), Celgene (Chair, Myeloid Neoplasms Repository Study); Speakers Bureau: AbbVie.
